

Efetividade de Materiais Educacionais para Profissionais de Saúde e População geral Alvo enquanto Medidas Adicionais de Minimização de Risco para Vabysmo[®], Eylea[®] e Lucentis[®] - O Estudo MARVEL

First published: 21/09/2023

Last updated: 21/09/2023

Study

Planned

Administrative details

EU PAS number

EUPAS106809

Study ID

106810

DARWIN EU[®] study

No

Study countries

 Portugal

Study description

Ophthalmological diseases affect all age groups and are increasingly prevalent. Pathologies such as age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and choroidal neovascularization (CNV) affect the posterior region of the eye, and have common treatment options available. The medicines Vabysmo®, Eylea® and Lucentis® are classified as Antineovascularization Agents and are used in the treatment of these ocular pathologies. Educational programs aim to adequately inform patients about the risks associated with the medicine, and as such their effectiveness must be guaranteed.

Study status

Planned

Research institutions and networks

Institutions

[Association for Innovation and Biomedical Research on Light and Image \(AIBILI\)](#)

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Contact details

Study institution contact

Joana Abrantes ufc@aibili.pt

Study contact

ufc@aibili.pt

Primary lead investigator

Liseta Lemos

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 01/09/2023

Study start date

Planned: 15/09/2023

Data analysis start date

Planned: 31/10/2023

Date of final study report

Planned: 30/11/2023

Sources of funding

- Other

More details on funding

INFARMED I.P..

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study type:

Non-interventional study

Scope of the study:

Assessment of risk minimisation measure implementation or effectiveness

Main study objective:

The objective of the study is to evaluate the effectiveness of educational materials designed to healthcare professionals and patients used as additional risk minimisation measures for Vabysmo® (faricimab), Eylea® (aflibercept) and Lucentis® (ranibizumab).

Study Design

Non-interventional study design

Cohort

Population studied

Age groups

- Adults (18 to < 46 years)
 - Adults (46 to < 65 years)
 - Adults (65 to < 75 years)
 - Adults (75 to < 85 years)
 - Adults (85 years and over)
-

Estimated number of subjects

500

Study design details

Outcomes

For healthcare professionals and the general population target, evaluate: - Receiving and viewing educational materials used as additional risk minimisation measures for Vabysmo® (faricimab), Eylea® (aflibercept) and Lucentis® (ranibizumab). - The level of knowledge of the key messages described in the educational materials used as additional risk minimisation measures for Vabysmo® (faricimab), Eylea® (aflibercept) and Lucentis® (ranibizumab).

Data analysis plan

Descriptive statistics will be used. Frequency distributions with 95% confidence intervals (CI) will be calculated for all responses. The data will be stratified by target group: health care professionals and patients/caregivers and by medicine.

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Signed checklist for study protocols

[ENCePPChecklistforStudyProtocols_preenchido.pdf](#) (290.84 KB)

Data sources

Data sources (types)

[Other](#)

Data sources (types), other

Prospective patient-based data collection

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No